Source:http://linkedlifedata.com/resource/pubmed/id/15930941
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
435
|
| pubmed:dateCreated |
2005-6-2
|
| pubmed:abstractText |
Adjuvant treatment or filling agents have been recommended for reducing recurrence rates of giant-cell tumors of bone. However, reports of low recurrence rates without either caused us to question this concept. We retrospectively reviewed 193 patients treated during a 27-year period, comparing our results with historic controls. One hundred thirty-seven patients had curettage as a primary treatment, and of these, 26 (19%) had local recurrences. The local recurrence rate of giant-cell tumors confined to bone (Campanacci Grades I and II) was only 7% compared with 29% in tumors with extraosseous extension (Campanacci Grade III). Six patients (4%) had a fracture after curettage. Twenty-nine patients who were referred to us with local recurrences after treatment elsewhere had curettage, and 10 (34%) of these patients had local recurrences develop. Twenty-seven patients had excision as their primary treatment, and two (7%) of these patients had local recurrence develop. We recommend primary curettage for intraosseous giant-cell tumors without adjuvant treatment or filling agents, but tumors with soft tissue extension or with local recurrence require more aggressive treatment. LEVEL OF EVIDENCE: Therapeutic study, Level IV (case series--no, or historical control group). See the Guidelines for Authors for a complete description of levels of evidence.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0009-921X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
211-8
|
| pubmed:meshHeading |
pubmed-meshheading:15930941-Adult,
pubmed-meshheading:15930941-Bone Neoplasms,
pubmed-meshheading:15930941-Chi-Square Distribution,
pubmed-meshheading:15930941-Curettage,
pubmed-meshheading:15930941-Female,
pubmed-meshheading:15930941-Fractures, Spontaneous,
pubmed-meshheading:15930941-Giant Cell Tumor of Bone,
pubmed-meshheading:15930941-Humans,
pubmed-meshheading:15930941-Male,
pubmed-meshheading:15930941-Neoplasm Recurrence, Local,
pubmed-meshheading:15930941-Retrospective Studies,
pubmed-meshheading:15930941-Treatment Outcome
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone?
|
| pubmed:affiliation |
Royal Orthopaedic Hospital Oncology Service, Bristol Road South, Northfield, Birmingham B31 2AP, England.
|
| pubmed:publicationType |
Journal Article
|